DAR-0100A

DAR-0100A is a small molecule and a selective, full dopamine D1 receptor agonist. It is the active enantiomer of the racemic compound dihydrexidine. Developed and investigated primarily by Larry J. Siever and colleagues at the Mount Sinai School of Medicine and the James J. Peters VA Medical Center, DAR-0100A has been studied for its potential to ameliorate cognitive deficits, particularly working memory impairments, in patients with Schizotypal Personality Disorder (SPD) and schizophrenia. The drug targets D1 receptors in the prefrontal cortex, a region where dopamine signaling is critical for executive function and cognitive performance. In clinical trials, DAR-0100A was administered via intravenous infusion and demonstrated significant improvements in working memory performance compared to placebo, with a large effect size. It is generally well-tolerated, with transient side effects such as sedation, tachycardia, and hypotension.

Other names

dihydrexidine enantiomer(+)-dihydrexidine